Featured Studies

Doctors at the National Institutes of Health (NIH) are conducting a study on patients with clonal hematopoiesis of indeterminate potential (CHIP). Patients with CHIP have a genetic mutation that has been associated with blood cancer. The study will look at CHIP and try to determine its relationship to blood cancers and heart disease. The study will also try to discover other new organs or diseases that may be linked with.

Does your pace of life in the city affect your health? Researchers at the National Institutes of Health (NIH) are conducting a study of two neighborhoods in Washington, D.C. in relationship to the environmental stress and the health behaviors of White and African American women. This research study will work to determine if there is a significant connection between neighborhood environment and the impact in women's health.

The research study sets out to learn about changes in the genetic makeup of CLL during the early phase of treatment with venetoclax. The initial phase of venetoclax therapy can be medically and logistically challenging. Patients will receive expert medical care at the National Institutes of Health (NIH).

¿Está buscando un tratamiento para su condición de hígado graso no alcohólico (NAFLD, por sus siglas en inglés) o para la esteatohepatitis no alcohólica (NASH, por sus siglas en inglés)? Investigadores de los Institutos Nacionales de la Salud, buscan voluntarios para participar en este estudio. Por 30 semanas, los participantes recibirán semaglutide (medicina usada para la diabetes tipo 2), esto podría mejorar su hígado y ayudarle a perder peso. El estudio espera entender mejor el daño del hígado y los mejores tratamientos para las personas con estas condiciones.

Are you looking for a treatment for non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH)? Researchers at the National Institutes of Health (NIH) seek volunteers to participate in a research study. For 30 weeks, participants will receive a medication called semaglutide (typically used for Type 2 diabetes), aiming to improve their liver disease and help them lose weight. The study hopes to better understand liver damage and its treatment in people with these conditions. (En español)

Doctors at the National Institutes of Health (NIH) seek patients with thyroid cancer that spread outside the thyroid - to the lymph nodes, lungs or bones. The standard treatment in such situation is therapy with radioactive iodine (RAI). In this study, doctors will assess a new imaging tool - 124I PET/CT, which enables evaluation of how much iodine goes into the tumor. The study goal is to compare how much iodine goes into cancer cells after two different methods of stimulation of RAI uptake.

Gigantism is a condition characterized by excessive growth and height significantly above average, caused by over-production of growth hormone (GH) during childhood. Investigators at the National Institutes of Health (NIH) want to see if a drug that antagonizes growth hormone action, called pegvisomant, can help children and adolescents with gigantism.

Hepatocellular Carcinoma (HCC) is the fifth most common cancer in the world. Patients with advanced HCC survive an average of 6 to 9 months. Researchers at the National Institutes of Health are testing the use of an immunotherapy medication called durvalumab, with two other chemotherapy medications, doxorubicin-eluting beads and bevacizumab. This clinical research study will investigate if this combination of medications can stop the progression of HCC.

Join a National Institutes of Health (NIH) research study seeking mean men who have a genetic risk factor for developing prostate cancer. Researchers want to follow the prostate health of men who have specific genetic changes associated with prostate cancer to help them learn more about which men are at higher risk for prostate cancer.

National Cancer Institute (NCI) researchers are conducting a study of patients with IDH-mutated gliomas. This study will test whether stimulating the immune system using the drug nivolumab can shrink recurrent IDH-mutant gliomas with and without hypermutator phenotype or increase the time it takes for them to grow or spread.